
- /
- Supported exchanges
- / US
- / BBLG.NASDAQ
Bone Biologics Corp (BBLG NASDAQ) stock market data APIs
Bone Biologics Corp Financial Data Overview
Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's medical device NELL-1/DBM, an osteopromotive recombinant protein that provides target-specific control over bone regeneration. It also develops NELL-1/DBM fusion device used in lumbar spinal fusion. The company's NELL-1 platform technology used in delivering enhanced outcomes in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine. It serves spine surgeons and patients with a skeletal bone defect or bone-related condition in their spine. The company has a license agreement with the UCLA Technology Development Group to develop and commercialize NELL-1 for spinal fusion applications. Bone Biologics Corporation was founded in 2004 and is headquartered in Burlington, Massachusetts.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get Bone Biologics Corp data using free add-ons & libraries
Get Bone Biologics Corp Fundamental Data
Bone Biologics Corp Fundamental data includes:
- Net Revenue:
- EBITDA: -824 964
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-02-19
- EPS/Forecast: -0.65
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Bone Biologics Corp News

Bone Biologics Prices $5.0 Million Underwritten Public Offering
BURLINGTON, Mass., June 15, 2023--(BUSINESS WIRE)--Bone Biologics Corporation (NASDAQ: BBLG) ("Bone Biologics" or the "Company"), a developer of orthobiologic products for spine fusion markets, today ...


BBLG: BBLG Advances Crucial Technology and Solidifies Funding
By Brad Sorensen, CFA NASDAQ:BBLG READ THE FULL BBLG RESEARCH REPORT Bone Biologics (NASDAQ:BBLG) recently announced that it has received approval to begin pilot clinical trials with NB1 in spinal ...

Bone Biologics Effects 1-for-30 Reverse Stock Split
BURLINGTON, Mass., June 06, 2023--(BUSINESS WIRE)--Bone Biologics Corporation (NASDAQ: BBLG), a developer of orthobiologic products for spine fusion markets, announces that a 1-for-30 reverse stock sp...

BBLG: BBLG Has Solid Cash and Is Advancing Testing
By Brad Sorensen, CFA NASDAQ:BBLG READ THE FULL BBLG RESEARCH REPORT Bone Biologics (NASDAQ:BBLG) recently announced that it has received approval to begin pilot clinical trials with NB1 in spinal ...
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.